Effect of female reproductive risk factors with SVT on the risk of VT
| . | . | Patients, n (%) . | Controls, n (%) . | Crude OR (95% CI) . | Adjusted OR (95% CI) . |
|---|---|---|---|---|---|
| SVT history | Reproductive risk factors | ||||
| Negative | No | 857 (37) | 2177 (70) | Reference | Reference |
| Negative | Yes | 1212 (53) | 843 (27) | 3.7 (3.2-4.1) | 5.0 (4.3-5.8) |
| Positive | No | 124 (5) | 72 (2) | 4.4 (3.2-5.9) | 4.0 (2.9-5.4) |
| Positive | Yes | 128 (5) | 12 (1) | 27.1 (14.9-49.2) | 34.9 (19.1-63.8) |
| SVT history | OC use | ||||
| Negative | No | 416 (33) | 1046 (44) | Reference | Reference |
| Negative | Yes | 902 (57) | 642 (54) | 3.7 (3.1-4.3) | 4.0 (3.3-4.7) |
| Positive | No | 41 (3) | 18 (1) | 5.2 (2.9-9.4) | 5.1 (2.8-9.5) |
| Positive | Yes | 86 (7) | 5 (1) | 49.4 (18.0-135.9) | 43.0 (15.5-119.3) |
| SVT history | HT use | ||||
| Negative | No | 706 (81) | 1264 (91) | Reference | Reference |
| Negative | Yes | 41 (6) | 50 (4) | 1.3 (0.8-2.1) | 1.5 (0.9-2.4) |
| Positive | No | 108 (12) | 58 (4) | 3.4 (2.3-4.8) | 3.1 (2.1-4.5) |
| Positive | Yes | 12 (1) | 3 (1) | 5.8 (1.6-21.3) | 5.8 (1.6-21.6) |
| SVT history | Pregnancy | ||||
| Negative | No | 1171 (81) | 1607 (94) | Reference | Reference |
| Negative | Yes | 147 (10) | 81 (4) | 2.5 (1.9-3.3) | 2.4 (1.8-3.2) |
| Positive | No | 119 (8) | 23 (2) | 6.8 (4.2-10.9) | 5.6 (3.4-9.2) |
| Positive | Yes | 8 (1) | 0 | NA | NA |
| . | . | Patients, n (%) . | Controls, n (%) . | Crude OR (95% CI) . | Adjusted OR (95% CI) . |
|---|---|---|---|---|---|
| SVT history | Reproductive risk factors | ||||
| Negative | No | 857 (37) | 2177 (70) | Reference | Reference |
| Negative | Yes | 1212 (53) | 843 (27) | 3.7 (3.2-4.1) | 5.0 (4.3-5.8) |
| Positive | No | 124 (5) | 72 (2) | 4.4 (3.2-5.9) | 4.0 (2.9-5.4) |
| Positive | Yes | 128 (5) | 12 (1) | 27.1 (14.9-49.2) | 34.9 (19.1-63.8) |
| SVT history | OC use | ||||
| Negative | No | 416 (33) | 1046 (44) | Reference | Reference |
| Negative | Yes | 902 (57) | 642 (54) | 3.7 (3.1-4.3) | 4.0 (3.3-4.7) |
| Positive | No | 41 (3) | 18 (1) | 5.2 (2.9-9.4) | 5.1 (2.8-9.5) |
| Positive | Yes | 86 (7) | 5 (1) | 49.4 (18.0-135.9) | 43.0 (15.5-119.3) |
| SVT history | HT use | ||||
| Negative | No | 706 (81) | 1264 (91) | Reference | Reference |
| Negative | Yes | 41 (6) | 50 (4) | 1.3 (0.8-2.1) | 1.5 (0.9-2.4) |
| Positive | No | 108 (12) | 58 (4) | 3.4 (2.3-4.8) | 3.1 (2.1-4.5) |
| Positive | Yes | 12 (1) | 3 (1) | 5.8 (1.6-21.3) | 5.8 (1.6-21.6) |
| SVT history | Pregnancy | ||||
| Negative | No | 1171 (81) | 1607 (94) | Reference | Reference |
| Negative | Yes | 147 (10) | 81 (4) | 2.5 (1.9-3.3) | 2.4 (1.8-3.2) |
| Positive | No | 119 (8) | 23 (2) | 6.8 (4.2-10.9) | 5.6 (3.4-9.2) |
| Positive | Yes | 8 (1) | 0 | NA | NA |
All ORs for SVT alone and SVT combined with a reproductive risk factor were adjusted for age, BMI, smoking, malignancy, and family history of VT. The overall OR, and the ORs for OC and HT were adjusted for age, BMI, smoking, and family history of VT. The OR for pregnancy was adjusted for age.
HT, postmenopausal hormone therapy; OC, oral contraception; OR, odds ratio; VT, venous thrombosis.